<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00960336</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000633600</org_study_id>
    <secondary_id>ARCAGY-DOGMES</secondary_id>
    <secondary_id>ARCAGY-GINECO-BR106</secondary_id>
    <secondary_id>INCA-RECF0511</secondary_id>
    <secondary_id>EUDRACT-2007-002736-28</secondary_id>
    <secondary_id>SCHER-ARCAGY-DOGMES</secondary_id>
    <nct_id>NCT00960336</nct_id>
  </id_info>
  <brief_title>Doxorubicin Hydrochloride Liposome as First-Line Therapy in Treating Older Women With Metastatic Breast Cancer</brief_title>
  <official_title>Multicenter Study of PEGylated Liposomal Doxorubicin in Geriatric Oncology - Metastatic Breast Cancer - First-line Treatment PEGylated Liposomal Doxorubicin in Patients Older Than 70 Years, Breast Cancer Metastasis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ARCAGY/ GINECO GROUP</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>ARCAGY/ GINECO GROUP</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy, such as doxorubicin hydrochloride liposome, work in&#xD;
      different ways to stop the growth of tumor cells, either by killing the cells or by stopping&#xD;
      them from dividing.&#xD;
&#xD;
      PURPOSE: This phase II trial is studying how well doxorubicin hydrochloride liposome works as&#xD;
      first-line therapy in treating older women with metastatic breast cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Evaluate the effectiveness of pegylated liposomal doxorubicin hydrochloride, in terms of&#xD;
           objective response rate, in elderly women with metastatic breast cancer.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Determine the feasibility of this drug in these patients.&#xD;
&#xD;
        -  Evaluate chemotherapy-induced toxicities in these patients.&#xD;
&#xD;
        -  Assess the disease-free survival and overall survival of these patients.&#xD;
&#xD;
        -  Study the geriatric covariates.&#xD;
&#xD;
        -  Assess the covariates predictive of the hematopoietic reserve and the risk of febrile&#xD;
           neutropenia in these patients.&#xD;
&#xD;
      OUTLINE: This is a multicenter study.&#xD;
&#xD;
      Patients receive pegylated liposomal doxorubicin hydrochloride IV over 60-90 minutes on day&#xD;
      1. Treatment repeats every 28 days for 6 courses in the absence of unacceptable toxicity or&#xD;
      progressive disease.&#xD;
&#xD;
      After completion of study therapy, patients are followed up periodically for 2 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2008</start_date>
  <primary_completion_date type="Actual">May 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Response rate</measure>
    <time_frame>3 and 6 cures</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">59</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>single arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>pegylated liposomal doxorubicin hydrochloride</intervention_name>
    <arm_group_label>single arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed invasive ductal or lobular adenocarcinoma of the breast&#xD;
&#xD;
               -  Metastatic disease as confirmed by ≥ 1 of the following:&#xD;
&#xD;
                    -  Histology or cytology&#xD;
&#xD;
                    -  Radiology&#xD;
&#xD;
                    -  Elevated CA 15-3 levels&#xD;
&#xD;
          -  No HER2/neu overexpression by IHC or FISH&#xD;
&#xD;
          -  Measurable (≥ 10 mm) or evaluable disease&#xD;
&#xD;
               -  Bone lesions or isolated pleural effusion allowed&#xD;
&#xD;
          -  Hormone receptor status not specified&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  Postmenopausal&#xD;
&#xD;
          -  Life expectancy &gt; 3 months&#xD;
&#xD;
          -  ANC ≥ 1,500/mm^3&#xD;
&#xD;
          -  Platelet count ≥ 100,000/mm^3&#xD;
&#xD;
          -  Hemoglobin ≥ 9 g/dL&#xD;
&#xD;
          -  AST and ALT ≤ 2.5 times upper limit of normal (ULN) (5 times ULN if liver metastases&#xD;
             are present)&#xD;
&#xD;
          -  Alkaline phosphatase ≤ 5 times ULN&#xD;
&#xD;
          -  Bilirubin ≤ 2 times ULN&#xD;
&#xD;
          -  Creatinine clearance ≥ 30 mL/min&#xD;
&#xD;
          -  LVEF ≥ 50%&#xD;
&#xD;
          -  No congestive heart failure or other uncontrolled cardiac disease&#xD;
&#xD;
          -  No other malignancy within the past 5 years except for curatively treated carcinoma in&#xD;
             situ of the cervix, urothelial in situ carcinoma, or basal cell cancer&#xD;
&#xD;
          -  No prior hypersensitivity to anthracyclines&#xD;
&#xD;
          -  No psychological, familial, social, or geographical reason that would preclude study&#xD;
             follow-up&#xD;
&#xD;
          -  No serious illness or physical or mental condition resulting in a permanent disability&#xD;
             that may preclude successful treatment&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  No prior chemotherapy for metastatic disease&#xD;
&#xD;
          -  Prior adjuvant chemotherapy allowed&#xD;
&#xD;
               -  No development of metastatic disease within 6 months after completion of adjuvant&#xD;
                  anthracycline-based chemotherapy&#xD;
&#xD;
          -  No more than 300 mg/m² of prior doxorubicin hydrochloride or 600 mg/m² of prior&#xD;
             epirubicin hydrochloride in the adjuvant setting&#xD;
&#xD;
          -  More than 30 days since prior participation in another clinical trial&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>70 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Laure Chauvenet, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hotel Dieu de Paris</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hotel Dieu de Paris</name>
      <address>
        <city>Paris</city>
        <zip>75181</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>October 2014</verification_date>
  <study_first_submitted>August 14, 2009</study_first_submitted>
  <study_first_submitted_qc>August 14, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 17, 2009</study_first_posted>
  <last_update_submitted>October 28, 2014</last_update_submitted>
  <last_update_submitted_qc>October 28, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 29, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HER2-negative breast cancer</keyword>
  <keyword>recurrent breast cancer</keyword>
  <keyword>stage IV breast cancer</keyword>
  <keyword>invasive ductal breast carcinoma</keyword>
  <keyword>invasive lobular breast carcinoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

